Geode Capital Management’s Co-Diagnostics CODX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,972
| Closed | -$81.2K | – | 4538 |
|
|
2025
Q4 | $81.2K | Buy |
14,972
+4,306
| +40% | +$46.9K | ﹤0.01% | 4142 |
|
|
2025
Q3 | $110K | Hold |
10,666
| – | – | ﹤0.01% | 4107 |
|
|
2025
Q2 | $89.7K | Sell |
10,666
-740
| -6% | -$6.92K | ﹤0.01% | 4090 |
|
|
2025
Q1 | $106K | Sell |
11,406
-111
| -1% | -$2.12K | ﹤0.01% | 4016 |
|
|
2024
Q4 | $259K | Buy |
11,517
+808
| +8% | +$25.5K | ﹤0.01% | 3813 |
|
|
2024
Q3 | $402K | Buy |
10,709
+130
| +1% | +$4.99K | ﹤0.01% | 3678 |
|
|
2024
Q2 | $397K | Buy |
10,579
+765
| +8% | +$27.8K | ﹤0.01% | 3654 |
|
|
2024
Q1 | $330K | Hold |
9,814
| – | – | ﹤0.01% | 3766 |
|
|
2023
Q4 | $392K | Hold |
9,814
| – | – | ﹤0.01% | 3705 |
|
|
2023
Q3 | $312K | Sell |
9,814
-258
| -3% | -$9.75K | ﹤0.01% | 3798 |
|
|
2023
Q2 | $335K | Sell |
10,072
-578
| -5% | -$22.1K | ﹤0.01% | 3803 |
|
|
2023
Q1 | $473K | Hold |
10,650
| – | – | ﹤0.01% | 3667 |
|
|
2022
Q4 | $805K | Buy |
10,650
+496
| +5% | +$46.4K | ﹤0.01% | 3456 |
|
|
2022
Q3 | $977K | Buy |
10,154
+114
| +1% | +$15.9K | ﹤0.01% | 3402 |
|
|
2022
Q2 | $1.69M | Buy |
10,040
+1,226
| +14% | +$186K | ﹤0.01% | 3173 |
|
|
2022
Q1 | $1.63M | Buy |
8,814
+269
| +3% | +$55.7K | ﹤0.01% | 3363 |
|
|
2021
Q4 | $2.29M | Sell |
8,545
-5
| -0.1% | -$1.31K | ﹤0.01% | 3301 |
|
|
2021
Q3 | $2.5M | Buy |
8,550
+610
| +8% | +$178K | ﹤0.01% | 3258 |
|
|
2021
Q2 | $1.97M | Sell |
7,940
-6,577
| -45% | -$1.69M | ﹤0.01% | 3272 |
|
|
2021
Q1 | $4.15M | Buy |
14,517
+1,480
| +11% | +$591K | ﹤0.01% | 2880 |
|
|
2020
Q4 | $3.64M | Buy |
13,037
+1,021
| +8% | +$378K | ﹤0.01% | 2765 |
|
|
2020
Q3 | $4.9M | Buy |
12,016
+1,001
| +9% | +$514K | ﹤0.01% | 2409 |
|
|
2020
Q2 | $6.39M | Buy |
11,015
+6,972
| +172% | +$3.18M | ﹤0.01% | 2199 |
|
|
2020
Q1 | $924K | Buy |
4,043
+2,433
| +151% | +$422K | ﹤0.01% | 3054 |
|
|
2019
Q4 | $43K | Hold |
1,610
| – | – | ﹤0.01% | 4105 |
|
|
2019
Q3 | $49K | Hold |
1,610
| – | – | ﹤0.01% | 4063 |
|
|
2019
Q2 | $39K | Hold |
1,610
| – | – | ﹤0.01% | 4103 |
|
|
2019
Q1 | $51K | Hold |
1,610
| – | – | ﹤0.01% | 4018 |
|
|
2018
Q4 | $70K | Hold |
1,610
| – | – | ﹤0.01% | 3927 |
|
|
2018
Q3 | $126K | Hold |
1,610
| – | – | ﹤0.01% | 3882 |
|
|
2018
Q2 | $187K | Buy |
+1,610
| New | +$131K | ﹤0.01% | 3734 |
|
Other funds holding CODX
PAG
SAM
SS
HWA
DB
Geode Capital Management's CODX Position: Q1 2026 in Review
Geode Capital Management sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 14,972 shares — an estimated $81.2K sold.
Geode Capital Management first reported a position in CODX in Q2 2018 and held it in 31 quarters. The position peaked at $6.39M in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.
- Geode Capital Management reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
- Geode Capital Management sold 14,972 Co-Diagnostics shares in Q1 2026, an estimated $81.2K.
- Geode Capital Management first reported a position in Co-Diagnostics in Q2 2018 and held it in 31 quarters.
- Geode Capital Management's Co-Diagnostics position peaked at $6.39M in Q2 2020.
- 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.